Search results
Author(s):
A Mark Richards
Added:
3 years ago
Ideally biomarkers provide the clinician with assistance in one or more of: (i) diagnosis, (ii) prognosis, (iii) choice and titration of therapy, (iv) monitoring progression of disease and (v) assessing response to treatment. The best-established biomarkers in acute decompensated heart failure (ADHF) are the B-type natriuretic peptides (brain natriuretic peptide [BNP] and N-terminal of the…
View more
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either…
View more
Author(s):
Noel S Lee
,
Lori B Daniels
Added:
3 years ago
Today, natriuretic peptides are ubiquitously utilized for the diagnosis, treatment, and prognostication of heart failure in the Emergency Department, as well as inpatient and outpatient settings alike.1–5 These endogenous hormones counteract some of the most detrimental effects of heart failure. Given their clinical and physiological importance, the fact that a manuscript describing the…
View more
Author(s):
Hans-Peter Brunner-La Rocca
,
Sandra Sanders-van Wijk
Added:
3 years ago
Natriuretic peptides (NPs) are well established in the diagnostic process of heart failure (HF). Low levels of NPs are particularly useful to exclude heart failure (HF). Numerous studies, predominantly in patients presenting with acute onset of symptoms suspected of HF, have convincingly shown the value of NPs in this regard. A meta-analysis published in 2015 clearly summarised the value of brain…
View more
Author(s):
Hans-Peter Brunner-La Rocca
,
Sema Bektas
Added:
3 years ago
Although the first study on biomarker-guided therapy of chronic heart failure (HF) was published 15 years ago,1 there is still no real proof of the superiority of this approach as compared with standard therapy. The guidelines of the European Society of Cardiology simply state that: “several RCTs that evaluated natriuretic peptide-guided treatment (intensifying treatment in order to lower peptide…
View more
Author(s):
Joe Gallagher
,
Chris Watson
,
Patricia Campbell
,
et al
Added:
3 years ago
Increasingly biomarkers are of interest in cardiovascular disease (CVD) for risk stratification. In particular, natriuretic peptides (NPs), which were originally used for the diagnosis of heart failure, are now finding a role in identifying those most at risk of heart failure and other cardiovascular (CV) disorders. Their ability to be measured rapidly through blood tests makes their widespread…
View more
Henry J Dargie
Job title: Consultant Cardiologist
Author
Author(s):
Nicholas Wettersten
,
Alan S Maisel
Added:
3 years ago
Cardiac troponin (cTn) is the core biomarker for the diagnosis of a myocardial infarct (MI).1 Indeed, as stated in Table 1, it meets all the definitions of a biomarker for acute coronary syndrome (ACS), as suggested by Maisel.2 In the setting of ACS, in addition to its diagnostic use, it is prognostic, clinically actionable and can be monitored during therapy as a surrogate of improvement. In…
View more
Author(s):
Joseph Gallagher
,
Kenneth McDonald
,
Mark Ledwidge
,
et al
Added:
3 years ago
Patients with heart disease in Africa commonly present with heart failure both for admission to hospital1 and in the outpatient setting.2 Recent data suggests that, in line with high income countries, heart failure with preserved ejection fraction is also becoming more common.3 Data from the 12 clinical studies performed before 2005 in eight sub-Saharan Africa (SSA) countries have shown that up…
View more